Azeliragon
- Generic Name
- Azeliragon
- Drug Type
- Small Molecule
- Chemical Formula
- C32H38ClN3O2
- CAS Number
- 603148-36-3
- Unique Ingredient Identifier
- LPU25F15UQ
- Background
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval
• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.
• Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages.
• Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.
Cantex Pharmaceuticals' Azeliragon Receives FDA Orphan Drug Designation for Breast Cancer Brain Metastasis
• Cantex Pharmaceuticals' azeliragon has been granted FDA Orphan Drug Designation for treating brain metastasis from breast cancer, addressing a critical unmet need.
• Azeliragon, an oral RAGE inhibitor, has shown promise in preclinical data and clinical safety trials, potentially overcoming resistance to radiation and disease progression.
• This designation provides Cantex with seven years of marketing exclusivity, along with benefits like assistance in drug development and tax credits.
• Cantex is actively investigating azeliragon in clinical trials for various cancers, including glioblastoma, breast, and pancreatic cancer, based on its safety profile.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath